arrows arrow-right arrow-left menu search rss youtube linkedin twitter facebook instagram arrow-play linkedIn

ASGCT 24th Annual Meeting

  • Dates:
    May 11
     - 
    May 14, 2021
  • Location: Virtual
Battelle is proud to be a part of the ASGCT Annual Meeting.

Where to Find Us

Tuesday, May 11
8:00am-10:00am 
Presentation:
  Cationic Diblock Copolymer Nanopaticles Improve Intercellular Delivery of Large pDNA Payloads
Presenter: Kenneth R. Sims Jr., PhD

Resized headshot








After graduating from Lehigh University with a B.S. in Bioengineering in 2008, Dr. Kenneth Sims Jr. began his career at Merck & Co., Inc. in West Point, Pennsylvania for six years as a sterile process and technology engineer with increasing levels of responsibility, eventually becoming the MMR® II vaccine subject matter expert in formulation, filling, and lyophilization. In these roles, he supported a variety of aspects of liquid and lyophilized vaccine manufacturing at West Point and in Durham, North Carolina, including deviation management, change control, process monitoring and verification, distribution and logistics, regulatory inspections, and response writing. While at Merck, Dr. Sims also completed a MS in Molecular Medicine at the Drexel University College of Medicine in Philadelphia, PA in 2013, which ultimately motivated him to pursue a PhD in Translational Biomedical Science at the University of Rochester School of Medicine and Dentistry in upstate New York starting in 2014. He finished his doctorate focused on advancing anti-biofilm polymer nanoparticle drug delivery systems in August 2019. After a brief post-doc at the University of Rochester focused on vaccine and drug delivery biomaterials development, Dr. Sims joined Battelle Memorial Institute at the beginning of March 2020, just as COVID-19 began affecting the United States. At Battelle, Dr. Sims has supported the CCDSTM Critical Care Decontamination System effort to sterilize PPE for front line workers during the COVID-19 pandemic, multiple drug delivery projects for pharmaceutical clients, and several internal research and development projects focused on nanoparticle development and non-viral gene delivery.